by Pete Celano | Aug 28, 2025 | Uncategorized
The Hepatoscope® from E-Scopics Big news here from 08/27/2025: “FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events.”The key paragraph:”The proposed biomarker offers a non-invasive...
by Pete Celano | Aug 27, 2025 | Uncategorized
Here’s a concise summary of the article titled “FIB-4-based Referral Pathways Have Suboptimal Accuracy to identify Increased Liver Stiffness and Incident Advanced Liver Disease” from July of 2025, as published in Clinical Gastroenterology and Hepatology.The...
by Pete Celano | Aug 22, 2025 | Uncategorized
From August 7, 2025MINNEAPOLIS–(BUSINESS WIRE)–HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition by a syndicate of globally recognized private...
by Pete Celano | Aug 15, 2025 | Uncategorized
Here’s a summary of the JAMA Health Forum research letter titled “Projected Savings From Reducing Low-Value Services in Medicare,” published on August 1, 2025: Key Findings The study conducted a cross-sectional analysis examining 47 identified low-value services...
by Pete Celano | Aug 8, 2025 | Press
Episode 6.10 – “New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening” from the podcast Surfing the MASH Tsunami by Roger Green. “LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos...
